Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2005, p. 1560-1568, Vol. 25, No. 4
0270-7306/05/$08.00+0 doi:10.1128/MCB.25.4.1560-1568.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Cell Cycle Control and Carcinogenesis, DKFZ, German Cancer Research Center, Heidelberg, Germany1
Received 22 October 2004/ Accepted 10 November 2004
|
|
|---|
|
|
|---|
After binding to origin DNA, ORC recruits two other proteins, cdc6 and cdt1. The binding of cdc6 to origins may lead to stabilization of ORC binding to chromatin (34). ORC, cdc6, and cdt1 then cooperate to load the minichromosome maintenance (MCM) complex on chromatin in an ATP-dependent manner. Once replication begins, cdc6 is degraded in yeast (37) by the anaphase-promoting complex (36). In metazoans, levels of chromatin-bound cdc6 vary, being low in early G1 and then accumulating until cells enter mitosis (1, 10).
The MCM hexamer consists of the MCM2-MCM7 complex proteins (2, 8, 12), which are structurally related and highly conserved in eukaryotes. In vivo and in vitro studies have revealed that, in addition to the heterohexameric form, the proteins can form additional complexes with different combinations of the MCM proteins (25, 43). Biochemical analysis of the MCM complex showed that the human and fission yeast MCM4-MCM6-MCM7 complex contains DNA helicase activity in vitro (20, 26). Initiation of DNA replication is triggered by the cooperative action of at least two sets of protein kinases, cyclin-dependent kinases and Dbf4-Cdc7, which recruit cdc45 to origins of DNA replication (48). There is also good evidence that Cdc7 stimulates initiation by phosphorylating MCM2 (41). MCM proteins are essential for DNA replication and have been implicated in licensing DNA for replication in Xenopus egg extracts (7, 29). Replication origins that are no longer occupied by the MCM complex are inactive, and this period of inactivation persists into the next G1 phase, in which a new cycle of activity begins with the recruitment of the MCM2-MCM7 complex.
Besides binding to cdc45, the MCM2-MCM7 complex also interacts with another replication initiation factor, MCM10, that is required for chromosomal DNA replication and stable plasmid maintenance in S. cerevisiae (33). Homologues of this gene have been identified in other organisms, including S. pombe, Xenopus laevis, and humans (3, 21, 45). In S. cerevisiae, MCM10 is a component of the pre-RC and is required for the association of the MCM complex with origin DNA (19). In S. cerevisiae and S. pombe, MCM10 is constitutively chromatin bound (16, 19). The binding of Xenopus MCM10, however, is not required for origin binding of Xenopus MCM2-MCM7 (45). Instead, the chromatin binding of MCM2-MCM7 is required for the chromatin association of MCM10, which in turn facilitates the binding of cdc45 to origins. Human MCM10 binds chromatin at the G1- to S-phase transition, but its function in the regulation of chromatin binding of the MCM2-MCM7 hexamer is not clear (22).
Another MCM family member, MCM8, contains the typical MCM domain and functional motifs of the MCM2-MCM7 proteins. Unlike MCM2-MCM7 and MCM10, MCM8 does not have a direct counterpart in yeast but is expressed in several higher eukaryotes (15).
In this paper, we show that human MCM8 (hMCM8) binds to chromatin during the cell cycle. Down-regulation of endogenous hMCM8 with small hairpin RNAs (sh-RNAs) in HeLa cells interferes with their ability to enter S phase. Furthermore, we found that human MCM8 interacts with two components of the pre-RC, hORC2 and hcdc6. In addition, inhibition of hMCM8 function by RNA interference (RNAi) leads to a reduced binding of hcdc6 to chromatin, suggesting an important function for hMCM8 in the assembly of the pre-RC.
|
|
|---|
Antibodies. To generate the N-terminal anti-hMCM8 polyclonal antibody [MCM8(1-92)], a fragment of hMCM8 (amino acids 1 through 92) was overexpressed in E. coli and purified as a GST-tagged fusion protein by using glutathione Sepharose (Sigma). Immunization of the rabbit was done by C. River. The C-terminal antibody [MCM8(741-756)] was raised against a synthetic peptide corresponding to amino acids 741 through 756 conjugated to keyhole limpet hemocyanin. The peptide synthesis and immunization of the rabbit were performed by Innovagen (Lund, Sweden). The terminal blood samples containing both antibodies were further purified on affinity columns. Anti-hORC2 was a kind gift from B. Stillman (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Anti-hMCM10 was kindly provided by F. Hanaoka (Institute for Molecular and Cellular Biology and CREST, Osaka University, Osaka, Japan). Anti-cyclin B was used as previously described (18). Antibodies to MEK1 and MEK2 were obtained from BioLabs, and anti-hMCM2 (N-19), anti-hMCM3 (G-19), anti-hMCM6 (C-20), and anti-hcdc6 (180.2) were obtained from Santa Cruz Biotechnology (Santa Cruz, Calif.). Anti-hPAN-MCM was purchased from BD PharMingen, and the monoclonal antibody 3F10 (anti-HA) was from Roche.
Cell culture and cell manipulations. The cell lines HeLa, Hs68, and 293T were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. HeLa cells were synchronized in S phase by treatment with 10 mM hydroxyurea (Sigma) and were harvested 18 h later by trypsinization. To synchronize HeLa cells at prometaphase, cells were treated with 50 ng of nocodazole (Sigma)/ml for 12 h. Cells were harvested by mitotic shake-off or released from a nocodazole block by being washed five times in medium without nocodazole and were then reseeded into fresh medium. For a G1-phase population, cells were harvested 8 h after their release from the block. The remaining cells after the mitotic shake-off were harvested by trypsinization to obtain cells in G2 phase. For time course studies, cells were harvested at the indicated time points after nocodazole release, washed once in phosphate-buffered saline, and used to prepare total cell extracts or subjected to biochemical fractionation, as described previously (30). For cytofluorometric analysis of DNA content, an aliquot of 2 x 105 cells was fixed in 70% ethanol. After fixation overnight at 20°C, cells were collected by centrifugation and treated with RNase (50 mM Tris-HCl at pH 7.5, 10 mM MgCl2, 10 µg of RNase A [Roche]/ml) for 30 min at 37°C. The cells were stained overnight on ice with propidium iodide (35 µg/ml, Sigma). Stained cells were analyzed with a Becton Dickinson FACScan. The data were analyzed with Cellquest software (Becton Dickinson).
Immunoblots and immunoprecipitations.
For Western blotting, cells were lysed in lysis buffer (50 mM Tris-HCl [pH 7.5], 250 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 50 mM NaF) supplemented with protease inhibitors (aprotinin, leupeptin, soybean trypsin inhibitor, TPCK [tosylsulfonyl phenylalanyl chloromethyl ketone], TLCK, [N
-p-tosyl-L-lysine chloromethyl ketone], and phenylmethylsulfonyl fluoride) for 30 min on ice, followed by centrifugation at 15,000 x g for 10 min, or they were subjected to biochemical fractionation (30). Extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A standard protocol for immunoblotting was used (17), and antibodies were used according to the manufacturer's instructions. Both anti-MCM8(1-92) and anti-MCM8(741-756) antibodies were used in a 1:1,000 dilution (0.2 µg/ml). For immunoprecipitations, 293T cells were transfected by using the standard calcium phosphate transfection protocol and harvested 36 h later. Cells were lysed, as described by Sommer et al. (42), in L buffer (140 mM NaCl, 2.6 mM KCl, 2 mM Na2HPO4, 1.45 mM KH2PO4, 1% Nonidet P-40, 0.5% aprotinin, 50 mM ß-glycerolphosphate, 10 mM NaF), supplemented with 50 U of RNase-free DNase I (Roche)/ml and 5 mM MgCl2, incubated on ice for 30 min, and cleared by centrifugation at 18,000 x g. Extracts were incubated overnight (at 4°C with rotation) with protein G-Sepharose (Pharmacia) and anti-HA antibody and then washed three times with L buffer. Beads were resuspended in SDS sample buffer, boiled for 10 min, and subjected to SDS-PAGE, followed by immunoblotting. For immunoprecipitation of endogenous proteins, HeLa cells were lysed in L buffer (42) supplemented with 50 U of DNase I/ml and 5 mM MgCl2, incubated on ice for 60 min, and cleared by centrifugation. MCM8 was immunoprecipitated by using the anti-MCM8(741-756) antibody. As a negative control, anti-MCM8(741-756) was preincubated with a 1,000 molar excess of the corresponding antigenic peptide for 15 min at room temperature.
RNA interference. The MCM8 targeting vector was based on a 19-mer sequence present in the coding sequence of human MCM8 (AGCGATAGCTCTCCTTTGA). Firefly luciferase (GL2) (14) was used as a control. Synthetic 64-mer oligonucleotides for cloning into pSuper (pS) were synthesized, annealed, and ligated into the pS construct as described previously (6). Cells were transfected by using the standard calcium phosphate transfection protocol. Where indicated for Fig. 5, cells were synchronized for 12 h with nocodazole at 60 h after transfection or were harvested at 48, 60, and 72 h after transfection and subjected to biochemical fractionation.
![]() View larger version (33K): [in a new window] |
FIG. 5. Loading of hcdc6 and hMCM proteins on chromatin is reduced after the down-regulation of hMCM8. Cells were transfected with pS-GL2 or pS-MCM8, harvested 48 (lane 1), 60 (lane 2), and 72 (lane 3) h later, and subjected to the biochemical-fractionation method as described in the legend to Fig. 2. Immunoblotting was carried out for total cell extract (TCE) (left panel) and the chromatin fraction (P3) (right panel) with antibodies against the indicated proteins. MEK1/MEK2, a cytosolic protein kinase, was used as a control.
|
|
|
|---|
![]() View larger version (24K): [in a new window] |
FIG. 1. Characterization of polyclonal antibodies generated against hMCM8. (A) Total cell extracts of HeLa, 293T (untransfected or transfected with hMCM8), and HS68 cells were subjected to SDS-PAGE, and proteins were transferred to nitrocellulose. After protein staining with Ponceau-S red (lower panel), the blot was cut and immunoblotted with either the C-terminal antibody [MCM8(741-756)], the N-terminal antibody [MCM8(1-92)], or the corresponding preimmune sera (PI) (upper panel). (B) Increasing amounts of recombinant His6-tagged hMCM8 (200, 400, and 800 ng) were subjected to SDS-PAGE, transferred to nitrocellulose, and immunoblotted with the polyclonal antibodies anti-hMCM8(1-92) and anti-hMCM8(741-756). Molecular mass markers (in kilodaltons) are noted at the left.
|
![]() ![]() View larger version (62K): [in a new window] |
FIG. 3. hMCM8 interacts with hcdc6 and hORC2 but not with the hMCM2-hMCM7 complex. (A) 293T cells were transfected with either HA-tagged hMCM8 (lanes 3 and 7), HA-tagged hcdc6 (lane 4), or HA-tagged ORC2 (lane 8). Untransfected 293T cells served as negative controls (lanes 2 and 6). Total cell extract of untransfected 293T cells (TCE) was used as the input control (lanes 1 and 5). Untransfected and transfected cells were incubated with anti-HA antibodies ( -HA) overnight. Immunoprecipitates (IP) were subjected to SDS-PAGE, and immunoblotting was carried out with the indicated antibodies. (B) HeLa cells were lysed and incubated with anti-MCM8(741-756) antibodies (MCM8) or anti-MCM8(741-756) antibodies preincubated with the corresponding antigenic peptide (MCM8+pep). Immunoprecipitates were subjected to SDS-PAGE and probed in immunoblots with the indicated antibodies.
|
![]() ![]() View larger version (65K): [in a new window] |
FIG. 2. hMCM8 is chromatin bound, and its chromatin binding is cell cycle regulated. (A) Asynchronous HeLa cells were subjected to a biochemical fractionation. In brief, cells were lysed with Triton X-100 in a sucrose-rich buffer. Cytoplasmic proteins (S2) were separated from the nuclei by low-speed centrifugation. Nuclei were washed and then lysed in a no-salt buffer. A second centrifugation step separated the remaining soluble nuclear proteins (S3) from an insoluble fraction (P3). Proteins found in the final pellet (P3) were likely to be bound to chromatin or the nuclear matrix. The distributions of different proteins in the total cell extract (TCE), soluble fraction (S2), solubilized nuclear proteins (S3), and chromatin-enriched fraction (P3), with or without micrococcal nuclease treatment (+ or ), are shown. (B) Chromatin association of hMCM8, the MCM2-MCM7 complex, hcdc6, and hORC2 during the cell cycle. HeLa cells were arrested at different stages of the cell cycle, the DNA content was determined by flow cytometry (upper panel), and an aliquot of cells was subjected to biochemical fractionation. Immunoblots of the soluble and insoluble fractions are shown (lower panel). The total cell extract of exponentially growing cells (TCE exp) was used as the input control. (C) Chromatin association of hMCM8 at the M- to G1-phase transition. HeLa cells were synchronized at prometaphase with nocodazole and then harvested by mitotic shake-off. Cells were collected at different time points after release from the block and subjected to biochemical fractionation (lower panel). The DNA contents of cells harvested at the indicated time points were determined by flow cytometry (upper panel).
|
RNAi-mediated down-regulation of hMCM8 impairs the G1-to-S transition. Since we observed hMCM8 associating with chromatin and interacting with components of the pre-RC, we asked whether hMCM8 function would be required for assembly of the pre-RC. We therefore determined whether down-regulation of endogenous hMCM8 by RNAi would prevent cells from entering S phase. To test this, we depleted hMCM8 mRNA in HeLa cells by using a vector that expressed sh-RNAs (6). Down-regulation was specific for hMCM8, since protein levels of other MCM family members were not affected (Fig. 5). Transfection of MCM8 sh-RNA (pS-MCM8) but not of the control vector (pS-GL2) resulted in a reduction of hMCM8 protein levels in Western blots with the MCM8(741-756) antibody, leading to a quantitative decrease of around 80% in the amount of endogenous hMCM8 protein at 72 h after transfection (Fig. 4A). We then analyzed by FACScan whether RNAi-mediated down-regulation of hMCM8 would lead to an increase in the amount of cells in G1 phase. We did, however, find only a small difference between the cell cycle distribution in pS-hMCM8 cells and that in control transfected cells (data not shown). Therefore, we studied the effect of hMCM8 down-regulation in synchronized cell populations. HeLa cells were transfected with pS-MCM8 or pS-GL2, treated with nocodazole to prevent reentry of the transfected cells into G1, and then analyzed by flow cytometry (Fig. 4B). The numbers indicate the amounts of cells in G1, S, or G2/M phase. It is conceivable that cells lacking hMCM8 function failed to enter prometaphase, most likely because they are not able to pass the G1- to S-phase transition. In fact, around 14% of the cell population remained in G1 phase after transfection of pS-hMCM8, whereas only 2% of the control transfected cells were found in G1. A significant population of the cells was also found in S phase in response to hMCM8 silencing (20% in MCM8-silcenced cells versus 10% in control cells). This outcome might be due to the possibility that cells that were not transfected with small hairpin MCM8 and therefore were not arrested in G1 or, alternatively, that they escaped the block because of residual amounts of MCM8. However, we cannot rule out the possibility that hMCM8 plays an additional role during S-phase progression. To further explore the function of hMCM8 at the G1- to S-phase transition, we performed an experiment similar to the one described in the legend to Fig. 4B, but this time, a time course experiment was carried out. HeLa cells were transfected with either pS-GL2 or pS-MCM8. At 60 h after transfection, cells were treated for 12 h with nocodazole, harvested by mitotic shake-off, washed five times, and reseeded into fresh medium. Samples were taken at indicated time points (Fig. 4C). We found that after removing the drug, cells in which hMCM8 was down-regulated passed the G1- to S-phase transition at a slower kinetics than control cells (Fig. 4C). In fact, while 44% of the hMCM8-silenced cells remained in G1 at 11 h after release from the block in control cells, only 19% remained in G1. These findings suggest that hMCM8 fulfills a role in G1 phase, since cells lacking the protein enter S phase with a significantly reduced kinetics. The fact that not all cells showed a block in G1 after the silencing of hMCM8 may be due to the incomplete down-regulation of hMCM8 protein levels following RNAi (Fig. 4A).
![]() View larger version (22K): [in a new window] |
FIG. 4. Down-regulation of hMCM8 by RNAi impairs the G1-to-S transition. (A) HeLa cells were transfected with either pS-MCM8 or pS-GL2, and the levels of hMCM8 were determined by immunoblotting at the indicated time points after transfection. (B) RNAi-mediated down-regulation of hMCM8 delays the G1-to-S transition. HeLa cells were transfected with either pS-GL2 or pS-MCM8, treated with nocodazole for 12 h at 60 h after transfection to prevent reentry of the transfected cells into G1, and analyzed by flow cytometry. (C) Down-regulation of hMCM8 leads to a delay in entry into S phase. HeLa cells were transfected with either pS-GL2 or pS-MCM8 and treated for 12 h with nocodazole. At 72 h after transfection, cells were harvested by mitotic shake-off, washed five times, and reseeded into fresh medium. Samples were taken at the indicated time points after release from the nocodazole block, and the DNA contents were determined by flow cytometry.
|
|
|
|---|
Whereas chromatin binding of the hMCM2-hMCM7 complex occurs only from G1 to early G2 phase, hMCM8 is bound to chromatin throughout the cell cycle (Fig. 2B). As previously shown by Gozuacik et al. (15) and as shown by this study (Fig. 3A), hMCM8 does not seem to interact directly with the hMCM2-hMCM7 complex in coimmunoprecipitation experiments, while other published data indicate that hMCM8 does associate with the hMCM2-hMCM7 complex proteins (23). This discrepancy might be explained by the use of different antibodies and buffer compositions. The facts that cdc6 is required for loading MCM2-MCM7 to chromatin (9, 44) and that a reduction of the amount of hMCM2-hMCM7 loaded onto chromatin was also observed upon down-regulation of hMCM8 by sh-RNAs (Fig. 5) lead us to conclude that a loose binding of hMCM8 to the hMCM2-hMCM7 complex might not be direct but rather mediated through hcdc6. Based on these findings, we present a model for human MCM8 function. At the end of mitosis, hMCM8 associates with hORC. hMCM8 then, in turn, recruits hcdc6 to origins of replication, possibly in cooperation with hcdt1. hcdc6 is required for the recruitment of the hMCM2-hMCM7 complex, resulting in the assembly of the pre-RC (Fig. 6). In a later step, the replicative helicase activity of the hMCM2-hMCM7 complex is induced through phosphorylation of the complex by two kinases, cdk2/cyclin E and cdc7/Dbf4. Then, hMCM10 also attaches to the complex and leads to the recruitment of cdc45 and other replication factors (Fig. 6).
![]() View larger version (12K): [in a new window] |
FIG. 6. Model describing the function of MCM8 as a loading factor for cdc6 to chromatin in human cells. See the text for details.
|
The execution point of MCM10 during the initiation of DNA replication has been a matter of debate. In S. cerevisiae, MCM10 is involved in the assembly of pre-RC by recruiting the MCM2-MCM7 complex and anchoring it to origins of DNA replication (19). Very recent results from the same group indicate that MCM10 also functions after pre-RC formation by recruiting cdc45 (40). Biochemical experiments with Xenopus MCM10 reveal that the protein clearly associates with chromatin after MCM2-MCM7 has bound (45) and is also required for the recruitment of cdc45 in this organism. We found that in human cells, hMCM10 is loaded to chromatin later than the hMCM2-hMCM7 complex (Fig. 2C). In addition, inhibition of hMCM10 function by RNAi does not lead to a reduction in the binding of hMCM2-hMCM7 to chromatin (data not shown), suggesting that in human cells, MCM10 is not involved in pre-RC formation. Our results suggest that human MCM8 participates in the activation of the pre-RC during G1 phase by recruiting cdc6 to the origin of DNA replication and that binding of cdc6 is required for origin binding of MCM2-MCM7. In the future, it will be intriguing to determine if hMCM8 is also required for the loading of Cdt1 to chromatin and how its function as a component of the pre-RC is regulated.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»